Your browser doesn't support javascript.
loading
Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma
Rovirosa, A; Valduvieco, I; Ascaso, C; Herreros, A; Bautista, C; Romera, I; Arenas, M; Pahisa, J; Biete, A.
Affiliation
  • Rovirosa, A; University of Barcelona. Hospital Clinic. Barcelona. Spain
  • Valduvieco, I; University of Barcelona. Hospital Clinic. Barcelona. Spain
  • Ascaso, C; University of Barcelona. Barcelona. Spain
  • Herreros, A; University of Barcelona. Hospital Clinic. Barcelona. Spain
  • Bautista, C; University of Barcelona. Hospital Clinic. Barcelona. Spain
  • Romera, I; University of Barcelona. Hospital Clinic. Barcelona. Spain
  • Arenas, M; Hospital General de Reus. Tarragona. Spain
  • Pahisa, J; Hospital Clínici. Barcelona. Spain
  • Biete, A; University of Barcelona. Hospital Clinic. Barcelona. Spain
Clin. transl. oncol. (Print) ; 15(2): 111-116, feb. 2013. tab
Article in English | IBECS | ID: ibc-127065
Responsible library: ES1.1
Localization: BNCS
ABSTRACT

PURPOSE:

To analyze the results of daily high-dose-rate brachytherapy (HDRBT) on local control and toxicity in the postoperative treatment of endometrial carcinoma (EC). MATERIALS AND

METHODS:

From January 2007 to September 2010, 112 patients were treated with HDRBT after surgery for EC. FIGO staging 24-IA, 48-IB, 14-II, 12-IIIA, 2-IIIB, 8-IIIC1 and 4-IIIC2. Pathology 99/112 endometrioid and 23/112 other types. Radiotherapy patients were divided into two groups-Group 1 (70/112) consists of external beam irradiation (EBI) plus HDRBT (2 fractions of 5-6 Gy) and Group 2 (42/112) consists of HDRBT alone (4 fractions of 5-6 Gy). Toxicity evaluation RTOG scores for bladder and rectum, and the objective criteria of LENT-SOMA for vagina. Statistics bivariate analysis of Chi-square and Fisher exact tests.

RESULTS:

With a mean follow-up of 29.52 months (range 9.60-53.57) no patient developed vaginal-cuff relapse. In Group 1 early toxicity appeared in 9 % in rectum, 8.5 % in bladder (G1-G2) and 1.4 % in vagina (G1); late toxicity was present in 8.5 % in rectum (all G1-G2 but 1 G3) and in 25 % in vagina (all G1-G2 but one G4). In Group 2, 9.4 % developed G1-G2 bladder and 6.9 % acute vagina (G1-G2) toxicity. Only 2.3 % had a G1 rectal score and 6.9 % had G1-G2 as vaginal scores for late problems.

CONCLUSIONS:

(1) Daily HDRBT using two fractions of 5-6 Gy after EBI and four fractions of 5-6 Gy as exclusive treatment was a safe regime. (2) Group 1 showed a higher incidence of late vaginal toxicity (AU)
Subject(s)
Search on Google
Collection: National databases / Spain Database: IBECS Main subject: Brachytherapy / Endometrial Neoplasms Limits: Aged / Female / Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2013 Document type: Article Institution/Affiliation country: Hospital Clínici/Spain / Hospital General de Reus/Spain / University of Barcelona/Spain
Search on Google
Collection: National databases / Spain Database: IBECS Main subject: Brachytherapy / Endometrial Neoplasms Limits: Aged / Female / Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2013 Document type: Article Institution/Affiliation country: Hospital Clínici/Spain / Hospital General de Reus/Spain / University of Barcelona/Spain
...